



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang

Christopher J. Walsh
W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel
Kevin W. McCabe

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

January 3, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8858

INTERNET ADDRESS:
JHEIDER@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Missing Parts
Art Unit 1635
Confirmation No.: 3427

Re: U.S. Utility Patent Application
Application No. 10/530,951; § 371 Date: August 18, 2006
For: **Genes Overexpressed By Ovarian Cancer and Their Use In**
Developing Novel Therapeutics
Inventors: HARIHARAN *et al.*
Our Ref: 2159.0620008/EKS/J-H

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF cover letter;
2. Request for Corrected Official Filing Receipt and Notice of Acceptance of Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.495;
3. A copy of the Official Filing Receipt, with corrections noted in red ink;
4. A copy of the Notice of Acceptance of Application under 35 U.S.C. 371 and 37 C.F.R. 1.495, with corrections noted in red ink;
5. A copy of the date-stamped return postcard dated May 26, 2006;
6. A copy of the Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address, previously filed on May 26, 2006;
7. A copy of the Request for Change of Attorney Docket Number Pleading, previously filed on May 26, 2006;
8. A copy of the return postcard from the filing of the Int'l Appl. No. PCT/US03/18253 dated June 10, 2003;

Commissioner for Patents
January 3, 2007
Page 2

9. A copy of the cover page of Published International Application No. PCT/US03/18253; and
10. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Julie A. Heider
Agent for Applicants
Registration No. 54,161

EKS/J-H/awt
Enclosures

625322_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARIHARAN *et al.*

Appl. No.: 10/530,951

§ 371 Date: August 18, 2006

For: **Genes Overexpressed By Ovarian
Cancer and Their Use In
Developing Novel Therapeutics**

Confirmation No.: 3427

Art Unit: 1635

Examiner: *To Be Assigned*

Atty. Docket: 2159.0620008/EKS/J-H

**Request for Corrected Official Filing Receipt and Notice of Acceptance of
Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.495**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Missing Parts

Sir:

Applicants hereby request that a corrected Official Filing Receipt and Notice of Acceptance of Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.495 be issued and sent to the undersigned representative.


Specifically, the following corrections to the Official Filing Receipt are requested: 1) Update Power of Attorney information per Revocation of Power of Attorney with New Power of Attorney filed May 26, 2006; 2) Remove asterisk from domestic priority data as filing date of International Application No. PCT/US03/18253 is correct (discussed below); and 3) Update Attorney Docket Number per Request for Change of Attorney Docket Number Pleading filed May 26, 2006. In support of the above request, a marked-up copy of the instant Official Filing Receipt is enclosed to show the corrections as well as copies of the Revocation of Power of Attorney with New Power, Request for Change of Attorney Docket Number and date stamped postcard indicating the filing of these documents on May 26, 2006.

Applicants also note that the I.A. Filing Date of International Application No. PCT/US03/18253, as indicated on the Notice of Acceptance of Application Under 35

U.S.C. § 371 and 37 C.F.R. § 1.495, is incorrectly indicated as December 10, 2004. The I.A. filing date of International Application No. PCT/US03/18253 is June 10, 2003. In support of the above request, a marked-up copy of the Notice of Acceptance of Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.495 is enclosed to show the correction as well as a copy of the date stamped postcard, indicating filing of Intl. Appl. No. PCT/US03/18253 on June 10, 2003, and a copy of the face page of the International Publication for Intl. Appl. No. PCT/US03/18253 indicating an I.A. filing date of June 10, 2003. Thus, the domestic priority claim of the present application, as indicated by Applicants, is correct. As such, it is requested that the I.A. filing date for International Application No. PCT/US03/18253 be corrected in PAIR and a corrected Official Filing Receipt and Notice of Acceptance of Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.495 be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Julie A. Heider
Agent for Applicants
Registration No. 54,161

Date: January 3, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
624363_1.DOC



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/530,951	08/18/2006	1635	1456	037003-0313914 2159. 0220008/EKS/J-H		52	3

CONFIRMATION NO. 3427

FILING RECEIPT



OC000000020913516

53644

STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
1100 NEW YORK AVE., N.W.
WASHINGTON, DC 20005

Date Mailed: 10/20/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)


Hariharan Kandasamy, San Diego, CA;
Mark Daniels, San Diego, CA;
Karen McLachlan, Del Mar, CA;

Assignment For Published Patent Application

Biogen Idec MA Inc., Cambridge, MA

Power of Attorney:

Practitioners Associated
~~Thomas Cawley Jr. 40944~~ with Customer Number
53644



Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/18253 06/10/2003*
which claims benefit of 60/386,748 06/10/2002
and claims benefit of 60/396,141 07/17/2002
and claims benefit of 60/405,319 08/23/2002
and claims benefit of 60/428,274 11/22/2002

~~(*)Data provided by applicant is not consistent with PTO records.~~

Foreign Applications

If Required, Foreign Filing License Granted: 10/19/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/530,951**

Projected Publication Date: 01/25/2007

Non-Publication Request: No

Early Publication Request: No

Title

Genes overexpressed by ovarian cancer and their use in developing novel therapeutics

Preliminary Class

536

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where


the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/530,951	Hariharan Kandasamy	037003-0313914

INTERNATIONAL APPLICATION NO.
PCT/US03/18253

I.A. FILING DATE	PRIORITY DATE
12/10/2004 06/10/2003	06/10/2002

53644

STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
 1100 NEW YORK AVE., N.W.
 WASHINGTON, DC 20005



CONFIRMATION NO. 3427
 371 ACCEPTANCE LETTER



OC000000020913517

Date Mailed: 10/20/2006

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>08/18/2006</u>	<u>08/18/2006</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 04/07/2005
- Copy of the International Search Report filed on 04/07/2005
- Copy of Article 19 Amendments filed on 08/18/2006
- Preliminary Amendments filed on 08/18/2006
- Information Disclosure Statements filed on 06/16/2006
- Biochemical Sequence Diskette filed on 04/07/2005
- Oath or Declaration filed on 08/18/2006
- Biochemical Sequence Listing filed on 08/18/2006
- U.S. Basic National Fees filed on 04/07/2005
- Power of Attorney filed on 05/26/2006

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)

Applicants: HARIHARAN *et al.*

Application No.: 10/530,951

Int'l Filing Date: June 10, 2003

For: **Genes Overexpressed By Ovarian Cancer and Their
Use In Developing Novel Therapeutics**

Due Date: NONE

Art Unit: *To Be Assigned*

Confirmation No.: *To Be Assigned*

Examiner: *To Be Assigned*

Docket: 2159.0620008

Atty: EKS/J-H




When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF cover letter;
 2. Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address;
 3. Statement Under 37 C.F.R. § 3.73(b), with a copy of the Assignment recorded April 11, 2006 and the Assignment recorded May 26, 2006 attached thereto. The Assignment documents were, or concurrently are, submitted for recordation pursuant to § 3.11;
 4. Request for Change of Attorney Docket Number Pleading; and
 5. One (1) return postcard.
- 537435_1.DOC

Please Date Stamp and Return to Our Courier



**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	10/530,951
Filing Date	June 10, 2003
First Named Inventor	Kandasamy HARIHARAN
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2159.0620008/EKS/J-H

I hereby revoke all previous powers of attorney given in the above-identified application.☐ A Power of Attorney is submitted herewith.**OR**☒ I hereby appoint the practitioners associated with the Customer Number:**53644**☒ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:**53644****OR**☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Signature

Name

Date

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.☒ Total of **1** forms are submitted.

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARIHARAN *et al.*

Application No.: 10/530,951

Int'l Filing Date: June 10, 2003

For: **Genes Overexpressed by Ovarian
Cancer and Their Use in
Developing Novel Therapeutics**

Confirmation No.: *To Be Assigned*

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2159.0620008/EKS/J-H

Request for Change of Attorney Docket Number Pleading

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the attorney docket number for the above-captioned application be changed from "037003-0304261" to -- 2159.0620008/EKS/J-H --. Kindly use this attorney docket number in any future correspondence addressed to the undersigned.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Julie A. Heider
Agent for Applicants
Registration No. 54,161

Date: May 26, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FOR PCT INTERNATIONAL APPLICATIONS ONLY

Applicant: IDEC PHARMACEUTICALS CORP. Due Date: June 10, 2003
PCT Int'l. Appin. No: TBA Agents Ref.: 37003/304261
PCT Int'l. Filing Date: 10 June 2003 Clt./Mat.: 37003-304261
Title: GENES OVEREXPRESSED BY OVARIAN. Atty.: ARH/TAC

The stamp of the US PTO acknowledges receipt of the following:

1. PCT Transmittal Letter (1 Sheets)
2. PCT Fee Calculation Sheet **PCT/US 03/18253**
3. Check No. _____ in the amount of \$ _____
4. PCT Request Form (6 Sheets)
5. _____ Appt of Agent or XX A copy of a General Power of Attorney
6. Description (97 Sheets); Claims (6 Sheets, No. 1-52);
Abstract (1 Sheet(s))
7. Drawings: 20 Sheets - Figures: 1-16 / Formal XX Informal
8. Other Documents:

UT20 Rec'd PCT/PTO 10 JUN 2003

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 2003/104429 A3

(51) International Patent Classification⁷: **A01N 61/00**,
37/18, A61K 38/28, 38/00, 51/00, 49/00, C07H 21/02,
21/04, C07K 16/00, G01N 33/567, 33/53

(74) Agents: CAWLEY, Thomas, A., Jr. et al.; Pillsbury
Winthrop LLP, P.O.Box 10500, Mclean, VA 22102 (US).

(21) International Application Number:
PCT/US2003/018253

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 10 June 2003 (10.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/386,748 10 June 2002 (10.06.2002) US
60/396,141 17 July 2002 (17.07.2002) US
60/405,319 23 August 2002 (23.08.2002) US
60/428,274 22 November 2002 (22.11.2002) US

(71) Applicant (*for all designated States except US*): IDEC
PHARMACEUTICALS CORPORATION [US/US];
3030 Callan Road, San Diego, CA 92121 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HARIHARAN,
Kandasamy [US/US]; 7414 Park Village Road, San
Diego, CA 92129 (US). DANIELS, Mark [US/US]; 4641
Max Drive, San Diego, CA 92115 (US). MCLACHLAN,
Karen [GB/US]; 184 W. Jason Street, Encinitas, CA
92024 (US).

(88) Date of publication of the international search report:
29 December 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: GENES OVEREXPRESSED BY OVARIAN CANCER AND THEIR USE IN DEVELOPING NOVEL THERAPEU-
TICS

(57) Abstract: Nucleic acid sequences encoding genes that are overexpressed by human ovarian cancers are provided. These genes and the corresponding antigens are useful diagnostic and therapeutic targets. The invention provides cancer therapies that target these antigens, especially using monoclonal antibodies that target the Anat-2 antigen.

WO 2003/104429 A3